<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682812</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A01335-48</org_study_id>
    <secondary_id>2007-30</secondary_id>
    <nct_id>NCT00682812</nct_id>
  </id_info>
  <brief_title>Significance of the High-risk Hpv Viral Load</brief_title>
  <official_title>Significance of the High-risk Hpv Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the significance of an elevated high-risk HPV (HR-HPV)
      viral load.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will particularly evaluate if the HR-HPV viral load:

        -  Is correlated to the transcription of the genes of the oncoproteins E6 and E7

        -  Is predictive of the integration of the virus in infected cells

        -  Is predictive of the presence of HPV in patients' blood

        -  Influences the local and systemic immunologic response
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the meaning of a viral load raised in HPV oncogenic</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the correlation enters the vorale load of the HPV oncogenic and the severity of the cervical hurt</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the correlation between the viral load of the HPV oncogenic and the level of transcription of the genes coding for oncoproteines E6 and E7</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the correlation between the viral load in HPV oncogenic and the integration of the viral genome in that of the infected cells</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the correlation between a viral load raised in HPV oncogenic and a presence of HPV in the circulating blood of the infected patients</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125 womens with normal cervix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>105 womens with an intraepithelial lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>105 womens with a cancer of the cervix</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 cervical takings and 2 sampling of blood</intervention_name>
    <description>2 cervical takings
2 sampling of blood before and after the total hysterectomy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 cervical takings and 2 sampling of blood</intervention_name>
    <description>cervical taking during the cervical conization
2 sampling of blood before and after the intervention</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 cervical takings and 2 sampling of blood</intervention_name>
    <description>cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation
2 sampling of blood before and after the intervention</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The women consulting for the therapeutic care (by hysterectomy or conization) of a
             LIEHG or a cervical cancer (carcinoma epidermoid or adenocarcinoma) confirmed by the
             anatomopathologique analysis of a preoperative cervical biopsy.

          -  The women having a normal cervix consulting for the surgical care by hysterectomy of a
             good-hearted pathology of the womb. The normality of the cervix will be confirmed by
             the anatomopathologique analysis of the detail of hysterectomy

          -  The patients participating in this study will have to be of more than 18 years old.
             All the subjects will be profitable of a regime of Social Security.

        Exclusion Criteria:

          -  The patients having a LIEBG

          -  The patients incapable to receive the information enlightened on the progress and the
             objectives of the study

          -  The patients not having signed enlightened assent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier CARCOPINO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique des Hopitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Nord, service de gynécologie-obstétrique</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

